

Product datasheet for TL311115V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Natriuretic Peptide Receptor C (NPR3) Human shRNA Lentiviral Particle (Locus ID 4883)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Natriuretic Peptide Receptor C (NPR3) Human shRNA Lentiviral Particle (Locus ID 4883)

Locus ID: 4883

Synonyms: ANP-C; ANPR-C; ANPRC; C5orf23; GUCY2B; NPR-C; NPRC

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: NPR3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000908, NM 001204375, NM 001204376, NM 000908.1, NM 000908.2, NM 001204376.1,

NM 001204375.1, BC022250, BC131540, NM 001363652, NM 001364460, NM 001364458,

NM 000908.4, NM 001204375.2

UniProt ID: P17342

Summary: This gene encodes one of three natriuretic peptide receptors. Natriutetic peptides are small

peptides which regulate blood volume and pressure, pulmonary hypertension, and cardiac function as well as some metabolic and growth processes. The product of this gene encodes a natriuretic peptide receptor responsible for clearing circulating and extracellular natriuretic peptides through endocytosis of the receptor. Multiple transcript variants encoding different

isoforms have been found for this gene.[provided by RefSeq, Feb 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Natriuretic Peptide Receptor C (NPR3) Human shRNA Lentiviral Particle (Locus ID 4883) – TL311115V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).